To evaluate efficacy against target protein-positive cancers, target protein-positive cells were created by introducing a gene expressing the target molecule into mogamulizumab (indication: CCR4-positive adult T-cell leukaemia) [24]. The gene discussed is CCR4; the disease is adult T-cell leukemia/lymphoma.